Publications by authors named "Michael Happich"

Claim this Profile
R
Reweighting Randomized Controlled Trial Evidence to Better Reflect Real Life - A Case Study of the Innovative Medicines Initiative.
Michael Happich, Alan Brnabic, Douglas Faries, Keith Abrams, Katherine B Winfree

Clin Pharmacol Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer's disease dementia.
Mark Belger, Josep Maria Haro, Catherine Reed, Michael Happich, Josep Maria Argimon

Eur J Health Econ· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical implications of using real-world evidence (RWE) in comparative effectiveness research: learnings from IMI-GetReal.
Amr Makady, Heather Stegenga, Antonio Ciaglia, Thomas Pa Debray, Michael Lees, Michael Happich

J Comp Eff Res· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study.
Catherine Reed, Michael Happich, Josep Maria Argimon, Josep Maria Haro, Anders Wimo

J Alzheimers Dis· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer's disease - the case of florbetapir.
John Hornberger, Jay Bae, Ian Watson, Joe Johnston, Michael Happich

Curr Med Res Opin· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to deal with missing longitudinal data in cost of illness analysis in Alzheimer's disease-suggestions from the GERAS observational study.
Mark Belger, Josep Maria Haro, Catherine Reed, Michael Happich, Kristin Kahle-Wrobleski

BMC Med Res Methodol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Excess Costs Associated with Possible Misdiagnosis of Alzheimer's Disease Among Patients with Vascular Dementia in a UK CPRD Population.
Michael Happich, Noam Y Kirson, Urvi Desai, Sarah King, Howard G Birnbaum

J Alzheimers Dis· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Do You Want to Hear the Bad News? The Value of Diagnostic Tests for Alzheimer's Disease.
Axel Mühlbacher, F Reed Johnson, Jui-Chen Yang, Michael Happich, Mark Belger

Value Health· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of societal costs in Alzheimer's disease: GERAS study baseline results.
Richard Dodel, Mark Belger, Catherine Reed, Anders Wimo, Roy W Jones, Michael Happich

Alzheimers Dement· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective.
John Hornberger, Steven Michalopoulos, Minghan Dai, Paula Andrade, Tatiana Dilla, Michael Happich

J Ment Health Policy Econ· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic literature review and meta-analysis of diagnostic test accuracy in Alzheimer's disease and other dementia using autopsy as standard of truth.
Sandrine Cure, Keith Abrams, Mark Belger, Grazzia Dell'agnello, Michael Happich

J Alzheimers Dis· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of pretreatment with antidepressants on the efficacy of duloxetine in terms of mood symptoms and functioning: an analysis of 15 pooled major depressive disorder studies.
Bruno R Barros, Alexander Schacht, Michael Happich, Foula Televantou, Lovisa Berggren

Prim Care Companion CNS Disord· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison.
Tatiana Dilla, Jörgen Möller, Paul O'Donohoe, María Álvarez, José A Sacristán, Michael Happich

BMC Psychiatry· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of duloxetine compared with pregabalin and gabapentin in diabetic peripheral neuropathic pain: results from a German observational study.
Michael Happich, Edith Schneider, Frank G Boess, Stefan Wilhelm, Alexander Schacht

Clin J Pain· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health care resource utilisation in primary care prior to and after a diagnosis of Alzheimer's disease: a retrospective, matched case-control study in the United Kingdom.
Lei Chen, Catherine Reed, Michael Happich, Allen Nyhuis, Alan Lenox-Smith

BMC Geriatr· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost effectiveness of duloxetine for osteoarthritis: a Quebec societal perspective.
Ronald C Wielage, Ankur J Patel, Megha Bansal, Shannon Lee, Robert W Klein, Michael Happich

Arthritis Care Res (Hoboken)· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis.
Julie Myers, Ronald C Wielage, Baoguang Han, Karen Price, James Gahn, Michael Happich

BMC Musculoskelet Disord· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.
Anders Wimo, Catherine C Reed, Richard Dodel, Mark Belger, Roy W Jones, Michael Happich

J Alzheimers Dis· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analyses of osteoarthritis oral therapies: a systematic review.
Ronald C Wielage, Julie A Myers, Robert W Klein, Michael Happich

Appl Health Econ Health Policy· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective-author response to letter to the editor.
Ronald C Wielage, Megha Bansal, J Scott Andrews, Madelaine M Wohlreich, Robert W Klein, Michael Happich

Value Health· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Authors' reply to Liedgens and Henske: "cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective".
Ronald C Wielage, Megha Bansal, J Scott Andrews, Robert W Klein, Michael Happich

Appl Health Econ Health Policy· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of duloxetine versus alternative oral therapies: an indirect comparison of randomised clinical trials in chronic low back pain.
Hélène Cawston, Alison Davie, Marie-Ange Paget, Vladimir Skljarevski, Michael Happich

Eur Spine J· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of diabetic peripheral neuropathic pain in primary care - a retrospective cohort study using the United Kingdom General Practice Research Database.
Catherine Reed, Jihyung Hong, Diego Novick, Alan Lenox-Smith, Michael Happich

Pragmat Obs Res· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.
Ronald C Wielage, Megha Bansal, J Scott Andrews, Robert W Klein, Michael Happich

Appl Health Econ Health Policy· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective.
Ronald C Wielage, Megha Bansal, J Scott Andrews, Madelaine M Wohlreich, Robert W Klein, Michael Happich

Value Health· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis